Prime time for prospective randomized trials of targeted therapies with validated targets in lung cancer: FDA perspective

被引：0
|
作者：
Malik, Shakun [1 ]
Justice, Robert [1 ]
Sridhara, Rajeshwari [1 ]
Waxman, Ian [1 ]
Pazdur, Richard [1 ]
机构：
[1] US FDA, CDER, Silver Spring, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S235 / S236
页数：2
相关论文
共 50 条
  • [41] 18F-Deoxyglucose Uptake in Stage I Non-Small-Cell Lung Cancer Time to Move to Randomized Trials
    De Ruysscher, Dirk
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (01) : 5 - 6
  • [42] Are we achieving the current waiting time targets in lung cancer treatment? Result of a prospective study from a large United Kingdom teaching hospital
    Devbhandari, Mohan P.
    Bittar, Mohammad N.
    Quennell, Pauline
    Barber, Philip
    Krysiak, Peotr
    Shah, Rajesh
    Jones, Mark T.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) : 590 - 592
  • [43] The Risk and Survival Significance of Immunotherapy and Targeted Therapy in Patients with Non -Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Tamene, B. A.
    Meng, Y.
    Danyang, Z.
    Kong, F. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E68 - E68
  • [44] FDA analysis: relationship between time-to-deterioration in cough, dyspnea, and/or pain in chest to clinical endpoints in non-small cell lung cancer (NSCLC) trials
    Vallejo, Jonathon
    Fiero, Mallorie
    Zhou, Jiaxi
    Royhouse, Jessica
    Kluetz, Paul
    Sridhara, Rajeshwari
    QUALITY OF LIFE RESEARCH, 2019, 28 : S56 - S56
  • [45] LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?
    Russo, Alessandro
    Muscolino, Paola
    Rolfo, Christian
    MED, 2024, 5 (02): : 112 - 114
  • [46] Which Should Be Used First for ALK-Positive Non-Small-Cell Lung Cancer: Chemotherapy or Targeted Therapy? A Meta-Analysis of Five Randomized Trials
    Lee, Yen-Chien
    Hsieh, Chung-Cheng
    Lee, Yen-Ling
    Li, Chung-Yi
    MEDICINA-LITHUANIA, 2019, 55 (02):
  • [47] Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials
    Nozawa, Kazuki
    Takatsuka, Daiki
    Endo, Yuka
    Horisawa, Nanae
    Ozaki, Yuri
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 174
  • [48] Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review
    Schoenmaekers, Janna Josephus Anna Oda
    Dursun, Safiye
    Biesmans, Charlotte
    Ruysscher, Dirk Karel Maria De
    Broen, Martinus Petrus Gertrudis
    Remon, Jordi
    Dingemans, Anne-Marie Clasina
    Hendriks, Lizza Elisabeth Lucia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 166
  • [49] Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses
    Liang, Wenhua
    Wu, Xuan
    Hong, Shaodong
    Zhang, Yaxiong
    Kang, Shiyang
    Fang, Wenfeng
    Qin, Tao
    Huang, Yan
    Zhao, Hongyun
    Zhang, Li
    PLOS ONE, 2014, 9 (10):
  • [50] Milestone analyses with immune checkpoint inhibitors (ICI), targeted therapy (TT), and standard therapy in metastatic non-small cell lung cancer (mNSCLC) trials submitted to the US FDA: An updated pooled analysis.
    Blumenthal, Gideon Michael
    Zhang, Lijun
    Zhang, Hui
    Kazandjian, Dickran
    Khozin, Sean
    Tang, Shenghui
    Sridhara, Rajeshwari
    Keegan, Patricia
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345